Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient

Liver Transpl. 2016 Feb;22(2):252-3. doi: 10.1002/lt.24353.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • 2-Naphthylamine
  • Anilides / therapeutic use*
  • Antiviral Agents / therapeutic use
  • Carbamates / therapeutic use*
  • Coinfection
  • Cyclopropanes
  • Drug Therapy, Combination
  • Genotype
  • Graft Survival
  • HIV Infections / complications*
  • Hepacivirus / genetics
  • Hepatitis C / complications
  • Hepatitis C / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lactams, Macrocyclic
  • Liver Transplantation / adverse effects*
  • Macrocyclic Compounds / therapeutic use*
  • Male
  • Middle Aged
  • Proline / analogs & derivatives
  • RNA, Viral / blood
  • Recurrence
  • Ritonavir / therapeutic use*
  • Sulfonamides / therapeutic use*
  • Treatment Outcome
  • Uracil / analogs & derivatives*
  • Uracil / therapeutic use
  • Valine

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Immunosuppressive Agents
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • RNA, Viral
  • Sulfonamides
  • ombitasvir
  • Uracil
  • Proline
  • 2-Naphthylamine
  • dasabuvir
  • Valine
  • Ritonavir
  • paritaprevir